"The beauty of this deal is that it's not just an out-licensing deal from Servier," CTI Life Sciences partner Jean-François Leprince told BioWorld Today as he explained newly formed Laval, Quebec-based Ilkos Therapeutics Inc., which made its debut with a $21 million three-way investment in equal parts by CTI, the Fonds de solidarité FTQ and Servier Canada.